This study showed that first‐ and second‐generation TKIs are not recommended for second‐line treatment in EGFR‐mutated NSCLC patients with T790M‐negative or unknown mutation that have received TKIs as first‐line treatment. Here, EGFR is linked to non-small cell lung carcinoma.